Animal health company Zoetis (NYSE:ZTS) will be announcing earnings results tomorrow before market hours. Here’s what investors should know. Zoetis met analysts’ revenue expectations last ...

Zoetis secured a USDA conditional license for its H5N2 avian flu vaccine for chickens, based on safety, purity, and serology-backed efficacy Over 150 million U.S. birds have been affected by ...

Investors were still wary of it after the latest earnings release. Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors know ...

Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance, presenting a buying opportunity around $163/share. Zoetis' unique advantages and pricing ...

Zoetis Q4 adjusted EPS rose to $1.40, beating estimates of $1.34, with sales of $2.32B, up 5%. Organic operational growth hit 9%. 2025 guidance projects revenue of $9.225B–$9.375B, with organic ...

PARSIPPANY, N. J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets ...

Zoetis Inc. (NYSE:ZTS) just released its quarterly report and things are looking bullish. The company beat expectations with revenues of US$2.4b arriving 4.2% ahead of forecasts. Statutory ...

Nov 4 (Reuters) - Zoetis (ZTS.N), opens new tab raised its annual profit and revenue forecasts on Monday on strong demand for its medicines and vaccines for animals. Shares of the animal ...

Zoetis is the undisputed leader in the global animal health industry, and we believe it possesses the widest moat of all the competitors. Zoetis has set itself apart based on its impressive ...

Zoetis, the global leader in animal health, has announced the expansion of its Global Capability Center in Hyderabad, a significant step in strengthening its presence in India. Over the coming ...